| Report | Question ID | Question | Discussion | Answer | Cancer Site Category | Data Item Category | Year |
|---|---|---|---|---|---|---|---|
|
|
20260030 | Reportability/Histology--Penis: Is a diagnosis of penile intraepithelial neoplasia (PeIN), HPV associated reportable and coded as 8077/2? See Discussion. |
Pathologists use the term "Penile intraepithelial neoplasm (PeIN), HPV associated" without a stated grade (e.g., PeIN, grade III) which we require to determine reportability. However, the WHO Classification of Urinary and Male Genital Tumors (5th ed.) includes the exact term "Penile intraepithelial neoplasia, HPV-associated" as 8077/2. This preferred term or synonym is not included in the Solid Tumor Rules, Other Sites, Table 23 (Penis and Scrotum Histologies). Is this diagnosis reportable without a stated grade (grade II or grade III)? Is this an exception to the high-grade squamous intraepithelial lesion code (8077/2)? |
Code histology and report PeIN, HPV-associated as 8077/2 (high-grade squamous intraepithelial lesion) using the Solid Tumor Rules, Other Sites, Table 23. The ICD-O coding is designated as “8077/2 high-grade squamous intraepithelial lesion” in the section “Penile intraepithelial neoplasia, HPV-associated” in the WHO Classification of Urinary and Male Genital Tumors (5th ed.). |
N/A | Histology | 2026 |
|
|
20260003 | Solid Tumor Rules/Histology--Thyroid: What is the correct histology for invasive encapsulated follicular variant of papillary thyroid carcinoma (IEFVPTC)? The 2026 Solid Tumor Rules (STR) Manual, Other Sites Table 12, conflicts with the ICD-O-3.2. See Discussion. |
STR Manual, Table 12, Thyroid Histologies, includes "Invasive encapsulated follicular variant of papillary thyroid carcinoma" as histology 8340/3 and is on its own row from other papillary thyroid carcinomas (PTC). A new footnote was added which states, "IEFVPTC and Infiltrative follicular variant of papillary thyroid carcinoma (a PTC subtype) share a histology code, but they are distinctly different histologies. They are on different rows of the table and are different primaries." However, IEFVPTC (and its synonyms) are listed in the ICD-O-3.2 as 8343/3, and 8343/3 was listed as a subtype/variant of papillary thyroid carcinoma in previous versions of the STR Manual. |
Assign histology as 8340/3 for IEFVPTC using the STR Manual, 2026 Update. Rule M18, Note 2, of the Other Sites STR state: Invasive encapsulated follicular variant of papillary thyroid carcinoma and Infiltrative follicular variant of papillary thyroid carcinoma share a histology code (8340) but are distinctly different entities. They are on separate rows of the table. WHO Classification of Endocrine and Neuroendocrine Tumors, 5th ed., indicates that after classic PTC, the follicular variant of PTC (FVPTC) is the second most common histological subtype of PTC. Two major forms are known, infiltrative FVPTC and invasive encapsulated FVPTC. The majority of follicular PTCs are encapsulated FVPTCs, whereas infiltrative FVPTC is quite rare and clinically behaves like classic PTC. |
Thyroid | Histology | 2026 |
|
|
20260006 | First Course of Therapy--Heme & Lymphoid Neoplasms: How is first course of treatment coded for hematopoietic and lymphoid neoplasm (heme) cases who are put on surveillance for years while asymptomatic and then start chemotherapy or other treatment years later once they become symptomatic? See Discussion. |
Patient was diagnosed with smoldering myeloma in October 2021 and put on surveillance. In May 2024, the patient became symptomatic and started chemotherapy. Is the date of diagnosis in 2021, with date of first treatment with chemotherapy in 2024? Or is active surveillance first course and treatment with chemotherapy as second course in 2024? |
Updated June 2026 Code the first course of treatment as active surveillance. Chemotherapy is second course of treatment based on this scenario due to progression. We will be adding clarification about this type of scenario to the treatment rules in the 2027 updates, which will be released October 2026. |
Heme & Lymphoid Neoplasms | N/A | 2026 |
|
|
20260009 | SEER Manual/Reportability/Date of Diagnosis--Prostate: How is the diagnosis date coded when a Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion is identified on imaging and therefore reportable, but further work-up or biopsy does not follow for 6 months or more? See Discussion. |
2026 SEER Manual Appendix E states PI-RADS (4 and 5) are reportable; they can be used to code the diagnosis date. The Date of Diagnosis Coding Instruction 3 in the SEER Manual states:The first diagnosis of cancer may be clinical (i.e., based on clinical findings or physician’s documentation) Note: Do not change the date of diagnosis when a clinical diagnosis is subsequently confirmed by positive histology or cytology. 2026 STORE Manual states: PI-RADS, BI-RADS, LI-RADs alone are not reportable for CoC. PI-RADS, BI-RADS, L-RADS confirmed with biopsy or physician statement are reportable to CoC. Date of diagnosis is the date of the positive biopsy or definitive statement from physician. Example: 01/04/2023 MRI identified both PI-RADS 4 and 5 lesions bilaterally. No work-up immediately followed and there is no chart information to account for the delay. The patient was seen again by urology and a 05/20/2024 biopsy proved adenocarcinoma. The patient underwent a prostatectomy approximately 6 months after biopsy on 01/13/2025. Biopsy diagnosis followed MRI diagnosis more than 16 months later and the plan was for active treatment. When further work-up does not shortly follow the MRI, and no information is available to the central registry to account for the delay, should the date of the biopsy be used to code diagnosis date? Using the SEER PI-RADS diagnosis in these cases makes it appear as if any first course treatment is often greater than 1 year after "diagnosis," when it is really only approximately 6 months after the biopsy. Which source should be used to code diagnosis date in these cases? Case 1: 01/04/2023 MRI identified both PI-RADS 4 and 5 lesions bilaterally. No work-up immediately followed and there is no chart information to account for the delay. The patient was seen again by urology and a 05/20/2024 biopsy proved adenocarcinoma. The patient underwent a prostatectomy approximately 6 months after biopsy on 01/13/2025. Biopsy diagnosis followed MRI diagnosis more than 16 months later and the plan was for active treatment. Case 2: 02/05/2024 MRI identified a PI-RADS 5 lesion. No work-up immediately followed and there is no chart information to account for the delay. The patient was seen again by urology and a 08/29/2024 biopsy proved adenocarcinoma. After consultation with the urologist, active surveillance was recommended on 01/27/2025. Biopsy diagnosis followed MRI diagnosis more than 6 months later and the plan was for active surveillance. |
Updated June 2026 Report PI-RADS 4 or 5 PI-RADS only when confirmed with biopsy or when based on a recognized medical practitioner statement. Use the date of diagnosis as the date of the positive biopsy or the definitive statement from the recognized medical practitioner, whichever is earlier. Use the date of biopsy in the two case scenarios based on the revised guidance. We will include this update in the next release of the SEER Manual. |
Prostate | Date of diagnosis | 2026 |
|
|
20260019 | Immunotherapy--Heme & Lymphoid Neoplasms: Should Anti-Thymocyte Globulin (ATG)/Cyclosporine/Prednisone be coded for myelodysplastic dysplastic syndrome (MDS) and if so, how should it be coded? See Discussion. |
Patient failed treatment with Azacitidine for MDS with multilineage dysplasia (9985/3) diagnosed 1/2024, and on re-biopsy of bone marrow 11/2025, histology is now MDS with excess blasts (9989/3). These diagnoses are the same primary using the Hematopoietic and Lymphoid Neoplasms (Heme) Database. The physician has prescribed treatment of Anti-Thymocyte Globulin (ATG)/Cyclosporine/Prednisone. SEER*Rx Database says not to code as ATG and Cyclosporine are antirejection medications post-transplant, but the oncologist is using this combination for treatment. |
Code ATG/Cyclosporine as biological response modifier (BRM)/Immunotherapy as first course of treatment using the current Heme Manual. Based on changes to the 2026 Heme rules for coding treatment, heme and lymphoid neoplasms are now treated differently than Solid Tumors when it comes to treatment failure. It can be used for treatment of selected MDS cases particularly those with low-risk disease, HLA-DR15 histocompatibility type, bone marrow hypoplasia. Prednisone should not be coded as it is not disease modifying agent in MDS. It is usually given to reduce/treat infusion reactions/serum sickness associated with ATG infusion. We will update SEER*Rx. |
Heme & Lymphoid Neoplasms | Immunotherapy | 2026 |
|
|
20260023 | SEER Manual/First Course Treatment/Other Therapy--Breast: How is the agent endoxifen coded when given to treat hormone sensitive breast cancer? This agent is not listed in SEER*Rx. |
Code as Other Therapy, code 2 (other-experimental). Endoxifen is currently in phase 2 studies and not FDA approved standard treatment at present. |
Breast | First course treatment, Other therapy | 2026 | |
|
|
20260012 | First Course of Therapy/Hormone Therapy--Thyroid: Is Thyrogen (thyrotropin alpha) coded as hormone therapy when a patient is given Thyrogen as part of planned 2-day Thyrogen Stimulated I-131 treatment for a papillary or follicular cancer? See Discussion. |
SEER*Rx categorizes Thyrogen as Hormones and hormonal mechanisms/Thyroid stimulating hormone. Probably not cancer directed–verify with attending MD. |
Do not code Thyrogen as hormone therapy when given as a stimulating agent in I-131 therapy. The therapeutic agent is I-131. The Thyrogen/thyroid stimulating hormone (TSH) is sensitizing the gland to absorb more I-131. Thyrogen/TSH is a trophic hormone so it can cause growth of cancer cells. Thyroid hormones are given in follicular and papillary thyroid cancers to suppress TSH. Although Thyrogen can promote cancer growth its use in Thyrogen stimulated I-131 radioactive therapy is justified (benefits exceed the risk), since the use is short (2 days) and the high amount of I-131 would kill cancer cells in addition to majority of thyroid tissue. We will update the Thyrogen entry in SEER*Rx and clarify in the next release of the SEER manual, Appendix C Coding Guidelines for Thyroid. |
Thyroid | First course treatment, Hormone Therapy | 2026 |
|
|
20260011 | Reportability/Histology--Breast: 2026: Is lobular neoplasia (atypical lobular hyperplasia) reportable? There is no mention of grade and or conclusive lobular carcinoma in situ (LCIS) statement given. |
Do not report a case of atypical lobular hyperplasia of the breast until/unless it is definitively diagnosed as LCIS or another reportable neoplasm. WHO defines this as a non-invasive lobular neoplasia. Atypical lobular hyperplasia does not have an ICD-O code and is not equivalent to in situ. |
Breast | Histology | 2026 | |
|
|
20260021 | First Course Treatment/Heme & Lymphoid Neoplasms--Multiple Myeloma: Is treatment for multiple myeloma coded as first-course treatment until patient achieves remission despite the possibility of progression due to a delay in treatment? A patient with multiple myeloma was advised treatment with Dara-RVD followed by a stem cell transplant. As the patient wanted to take care of another health issue, the patient waited 8 months to start treatment. |
Code treatment as first course of treatment, even though there was an 8-month delay. The patient's treatment plan was to delay the cancer treatment due to another health condition. When that health condition was resolved, then the cancer treatment was given. Patients do delay treatment for many different reasons, but most of them would not be 8 months. This fits the new rule which is all treatment is first course until remission. This is different from active surveillance, where the patient is being monitored for symptoms/disease progression. We have a clarification coming out in the 2027 updates that states if Active Surveillance is the planned treatment until symptoms appear, that any treatment received after active surveillance is second course. That is not the situation here. This is delayed therapy. |
Heme & Lymphoid Neoplasms | First course treatment | 2026 | |
|
|
20260024 | SEER Manual/First Course Treatment/Other Therapy--Uterus: Is Metformin coded to Other Therapy code 1 vs 6? Multiple GYN physicians have stated, “Adenocarcinoma of Endometrium, treating with intrauterine device and Metformin.” The patient is not on any specified trials. |
Code Other Therapy to 6 (Other-Unproven) since Metformin is not included in oncology guidelines and studies show controversial results at this time. |
Corpus uteri | Chemotherapy, First course treatment | 2026 |
Home
